Axon Enterprise, Inc. (AXON)

Intra-Cellular Therapies Stock Forecast

Stock Price Forecast

The 14 analysts that cover Intra-Cellular Therapies stock have a consensus rating of "Strong Buy" and an average price target of $798.57, which forecasts a 2.91% increase in the stock price over the next year. The lowest target is $550 and the highest is $1000.

Price Target: $798.57 (+2.91%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$550	$798.57	$830	$1000
Change	-29.12%	+2.91%	+6.96%	+28.87%

Analyst Ratings

The average analyst rating for Intra-Cellular Therapies stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Mar '25	Apr '25	May '25	Jun '25	Jul '25	Aug '25
Strong Buy	6	5	5	5	4	5
Buy	8	7	7	7	9	9
Hold	2	2	1	1	2	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	16	14	13	13	15	15

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jordan Lyonnais B of A Securities	B of A Securities	Strong Buy Maintains $895 → $1,000	Strong Buy	Maintains	$895 → $1,000	+28.87%	Aug 6, 2025
Jeremy Hamblin Craig-Hallum	Craig-Hallum	Hold → Strong Buy Upgrades $900	Hold → Strong Buy	Upgrades	$900	+15.98%	Aug 5, 2025
Brian Gesuale Raymond James	Raymond James	Buy Maintains $645 → $855	Buy	Maintains	$645 → $855	+10.18%	Aug 5, 2025
Andrew Spinola UBS	UBS	Hold Maintains $820 → $840	Hold	Maintains	$820 → $840	+8.25%	Aug 5, 2025
Joshua Reilly Needham	Needham	Strong Buy Maintains $820 → $870	Strong Buy	Maintains	$820 → $870	+12.11%	Aug 5, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

2.71B

Increased by 30.32%

from 2.08B

Revenue Next Year

3.35B

Increased by 23.36%

from 2.71B

EPS This Year

6.31

Increased by 31.44%

from 4.80

EPS Next Year

7.81

Increased by 23.85%

from 6.31

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	681.00M	863.38M	1.19B	1.56B	2.08B	2.71B	3.35B	3.99B
Revenue Growth	28.28%	26.78%	37.50%	31.47%	33.43%	30.32%	23.36%	19.09%
EPS	-0.03	-0.91	2.03	2.33	4.80	6.31	7.81	9.17
EPS Growth	-	-	-	14.78%	106.01%	31.44%	23.85%	17.39%
Forward PE	-	-	-	-	-	123.00	99.31	84.60
No. Analysts	-	-	-	-	-	19	19	7

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	2.8B	3.7B	4.3B
Avg	2.7B	3.3B	4.0B
Low	2.6B	3.1B	3.7B

Revenue Growth

Revenue Growth	2025	2026	2027
High	36.3%	36.1%	29.3%
Avg	30.3%	23.4%	19.1%
Low	23.6%	14.5%	10.5%

EPS Forecast

EPS	2025	2026	2027
High	7.80	10.55	10.20
Avg	6.31	7.81	9.17
Low	5.26	6.74	8.31

EPS Growth

EPS Growth	2025	2026	2027
High	62.5%	67.3%	30.5%
Avg	31.4%	23.9%	17.4%
Low	9.6%	6.9%	6.4%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.